Diagnostics

While discounts have come down, pricing gap still large between incumbents and new players

While discounts have come down, pricing gap still large between incumbents and new players

Online players had kept rates low, but with Covid time volumes gone, the trend is changing

Thyrocare is diagnostic chains that conduct an array of medical diagnostic tests and profiles of tests that centre on early detection and management of health disorders and diseases.

Fertility treatments chain Indira IVF on Tuesday announced a foray into the diagnostics sector with a Rs 60 crore investment over the next five years. The city-based company, which claims to India's largest fertility treatments chain, plans to offer pathology tests catering to the needs of women and children, as per an official statement. It plans to have over 30 laboratories by FY24, which will include centres in Lucknow, Patna, New Delhi, Mumbai, Pune, Udaipur, Jaipur, Varanasi, Kolkata, Ranchi, Bhubaneswar and Bengaluru, it said. The TA Associates-backed chain plans to invest Rs 50-60 crore for Indira Pathlabs over next five years which may even exceed depending on future plans and opportunities, the statement said.

Competitive pressures, valuations cap gains from current levels

Dr Reddy's Laboratories Ltd on Friday said its consolidated profit after tax (PAT) for the quarter ended September 30, 2022 was up by 12 per cent at Rs 1,112.80 crore as against Rs 992 crore in the same quarter a year ago. Revenues during the quarter under discussion were up by nine per cent to Rs 6,305.70 crore compared to Rs 5,215.40 crore in the first quarter of FY '22. Commenting on the results, Co-Chairman and MD, G V Prasad said, "We are pleased with the strong financial performance in the current quarter, driven by the launch of Lenalidomide capsules in the US market. Our focus is to build a robust pipeline with products that improve affordability and access to patients globally. We continue to progress well in our productivity, innovation and sustainability agenda.

A fall in Covid-19 tests will lead to an up to 7 per cent dent in diagnostic companies' toplines in FY23, rating agency Crisil said on Wednesday. The fall in revenues in FY23 will come after a handsome 30 per cent growth in FY22 on higher testing, the agency said, attributing the fall in Covid testing in the ongoing fiscal to the waning intensity of the pandemic and also a preference for self-test kits. The operating profit margins, which had hit a decadal high of 28 per cent in FY22, will moderate to 24-25 per cent in FY23 on the decline in revenue and the higher operating expenses, driven by advertising and marketing costs, it said. Good cash generation, prudent capital spends (mainly on diagnostic equipment) and low debt levels will keep balance sheets at healthy levels, resulting in 'stable' credit profiles for diagnostic players, the rating agency said. The agency said it has analysed 11 players in the industry having an aggregate revenue of over Rs 6,500 crore to arrive at th

It addresses the shortage of radiologists and pathologists and frees up doctors to deal with complex cases

Mainly a PPP and B2B player, the Pune-based chain offers disruptive pricing

The researchers said that the state-of-the-art technology uses magnetic resonance imaging (MRI) to create detailed 4D flow images of the heart.

The company is also open to raising funds and has been in talks with PE and VC funds for the same

In the past one year, these stocks have slipped between 48 per cent and 51 per cent, as compared to 3 per cent gain in the Sensex

A company called Torrent Diagnostics Private Ltd was incorporated in February this year and has a Torrent Pharmaceuticals executive director as one of its directors

Hospitals back to normalcy; tough road ahead for diagnostics

The federal jury in San Jose on Thursday found Pakistan-born Balwani, 57, guilty of two counts of conspiracy and ten counts of wire fraud through a multimillion-dollar scheme

Competitive pricing, however, is here to stay, feel analysts and some industry insiders

The company has signed definitive agreements with Achira Labs for the purpose, Cipla said in a regulatory filing

In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0

Experts believe the current news cycle may keep the stock prices of related players volatile in the near term, but any fundamental or direct impact, in the long run, remains improbable.